Silence Therapeutics PLC Results of Annual General Meeting (0091C)

TIDMSLN

RNS Number : 0091C

Silence Therapeutics PLC

15 June 2021

Results of Annual General Meeting

15 June 2021

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that at its Annual General Meeting held today, 15 June 2021, all resolutions set out in the notice of meeting were duly passed on a poll.

The votes were as follows:

 
 Resolution                  Votes        %         Votes      %       Votes        % of     Votes 
  *Indicates special          for                    against            total*       ISC      withheld 
  resolution                                                                         voted 
 1 - Receive and 
  adopt the 2020 
  UK Annual Report           36,083,741   100.00%          0   0.00%   36,083,741   40.23%      21,958 
                            -----------  --------  ---------  ------  -----------  ------- 
 2 - Re-appoint 
  Mark Rothera 
  as a director              36,030,331    99.79%     74,748   0.21%   36,105,079   40.26%         620 
                            -----------  --------  ---------  ------  -----------  ------- 
 3 - Re-appoint 
  Dr. Michael Davidson 
  as a director              36,080,250    99.93%     24,829   0.07%   36,105,079   40.26%         620 
                            -----------  --------  ---------  ------  -----------  ------- 
 4 - Re-appoint 
  Dr. Giles Campion 
  as a director              36,042,763    99.83%     62,316   0.17%   36,105,079   40.26%         620 
                            -----------  --------  ---------  ------  -----------  ------- 
 5 - Approve the 
  directors' remuneration 
  report                     35,285,210    97.73%    820,064   2.27%   36,105,274   40.26%         425 
                            -----------  --------  ---------  ------  -----------  ------- 
 6 - Approve the 
  directors' remuneration 
  policy                     35,240,884    97.61%    864,390   2.39%   36,105,274   40.26%         425 
                            -----------  --------  ---------  ------  -----------  ------- 
 7 - Re-appoint 
  PricewaterhouseCoopers 
  LLP as auditors 
  of the Company             27,375,812    97.44%    719,478   2.56%   28,095,290   31.33%   8,010,409 
                            -----------  --------  ---------  ------  -----------  ------- 
 8 - Authorise 
  the directors 
  to allot shares 
  and grant rights 
  to subscribe 
  for, or convert 
  securities into, 
  shares                     31,771,639    99.82%     57,480   0.18%   31,829,119   35.49%   4,276,580 
                            -----------  --------  ---------  ------  -----------  ------- 
 9 - Disapply 
  pre-emption rights 
  in connection 
  with an allotment 
  of equity securities 
  for cash*                  29,459,251    97.48%    761,703   2.52%   30,220,954   33.70%   5,884,745 
                            -----------  --------  ---------  ------  -----------  ------- 
 

The number of the Company's ordinary shares in issue as at the date of the meeting was 89,685,448 ordinary shares of nominal value 5p each.

*Excludes votes withheld.

A vote withheld is not a vote in law and has not been counted in the calculation of the proportion of votes for and against the resolutions.

Enquiries:

 
 Silence Therapeutics plc                              Tel: [phone] 
  Gem Hopkins, Head of IR & Corporate Communications 
  Investec Bank plc (Nominated Adviser and              Tel: +44 (0) 20 
   Broker)                                               7597 5970 
   Daniel Adams/Gary Clarence 
 European PR                                           Tel: +44 (0) 20 
  Consilium Strategic Communications                    3709 5700 
  Mary-Jane Elliott/Chris Welsh/Angela Gray 
  [e-mail] 
 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD(TM) platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFLFERRFIELIL

(END) Dow Jones Newswires

June 15, 2021 12:54 ET (16:54 GMT)